These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 32234426)

  • 41. ABCB1 and ABCG2, but not CYP3A4 limit oral availability and brain accumulation of the RET inhibitor pralsetinib.
    Wang Y; Sparidans RW; Potters S; Lebre MC; Beijnen JH; Schinkel AH
    Pharmacol Res; 2021 Oct; 172():105850. PubMed ID: 34450308
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tivozanib reverses multidrug resistance mediated by ABCB1 (P-glycoprotein) and ABCG2 (BCRP).
    Yang D; Kathawala RJ; Chufan EE; Patel A; Ambudkar SV; Chen ZS; Chen X
    Future Oncol; 2014 Aug; 10(11):1827-41. PubMed ID: 24295377
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Characterisation of the roles of ABCB1, ABCC1, ABCC2 and ABCG2 in the transport and pharmacokinetics of actinomycin D in vitro and in vivo.
    Hill CR; Jamieson D; Thomas HD; Brown CD; Boddy AV; Veal GJ
    Biochem Pharmacol; 2013 Jan; 85(1):29-37. PubMed ID: 23063411
    [TBL] [Abstract][Full Text] [Related]  

  • 44. PET-CT imaging with [(18)F]-gefitinib to measure Abcb1a/1b (P-gp) and Abcg2 (Bcrp1) mediated drug-drug interactions at the murine blood-brain barrier.
    Vlaming ML; Läppchen T; Jansen HT; Kivits S; van Driel A; van de Steeg E; van der Hoorn JW; Sio CF; Steinbach OC; DeGroot J
    Nucl Med Biol; 2015 Nov; 42(11):833-41. PubMed ID: 26264927
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Effects of cytochrome P450 3A (CYP3A) and the drug transporters P-glycoprotein (MDR1/ABCB1) and MRP2 (ABCC2) on the pharmacokinetics of lopinavir.
    van Waterschoot RA; ter Heine R; Wagenaar E; van der Kruijssen CM; Rooswinkel RW; Huitema AD; Beijnen JH; Schinkel AH
    Br J Pharmacol; 2010 Jul; 160(5):1224-33. PubMed ID: 20590614
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Sildenafil is not a useful modulator of ABCB1 and ABCG2 mediated drug resistance in vivo.
    Lin F; Hoogendijk L; Buil L; Beijnen JH; van Tellingen O
    Eur J Cancer; 2013 May; 49(8):2059-64. PubMed ID: 23422148
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Brain Accumulation of Ponatinib and Its Active Metabolite, N-Desmethyl Ponatinib, Is Limited by P-Glycoprotein (P-GP/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2).
    Kort A; van Hoppe S; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    Mol Pharm; 2017 Oct; 14(10):3258-3268. PubMed ID: 28880088
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Rifampin and ritonavir increase oral availability and elacridar enhances overall exposure and brain accumulation of the NTRK inhibitor larotrectinib.
    Wang Y; Sparidans RW; Wang J; Li W; Lebre MC; Beijnen JH; Schinkel AH
    Eur J Pharm Biopharm; 2022 Jan; 170():197-207. PubMed ID: 34952136
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier.
    Poller B; Wagenaar E; Tang SC; Schinkel AH
    Mol Pharm; 2011 Apr; 8(2):571-82. PubMed ID: 21309545
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Brain Distribution of Dual ABCB1/ABCG2 Substrates Is Unaltered in a Beta-Amyloidosis Mouse Model.
    Wanek T; Zoufal V; Brackhan M; Krohn M; Mairinger S; Filip T; Sauberer M; Stanek J; Pekar T; Pahnke J; Langer O
    Int J Mol Sci; 2020 Nov; 21(21):. PubMed ID: 33153231
    [TBL] [Abstract][Full Text] [Related]  

  • 51. P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) restrict brain accumulation of the active sunitinib metabolite N-desethyl sunitinib.
    Tang SC; Lankheet NA; Poller B; Wagenaar E; Beijnen JH; Schinkel AH
    J Pharmacol Exp Ther; 2012 Apr; 341(1):164-73. PubMed ID: 22238213
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) gene dosage on plasma pharmacokinetics and brain accumulation of dasatinib, sorafenib, and sunitinib.
    Tang SC; de Vries N; Sparidans RW; Wagenaar E; Beijnen JH; Schinkel AH
    J Pharmacol Exp Ther; 2013 Sep; 346(3):486-94. PubMed ID: 23843632
    [TBL] [Abstract][Full Text] [Related]  

  • 53. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Accumulation of the Novel EGFR Inhibitor EAI045 and Oral Elacridar Coadministration Enhances Its Brain Accumulation and Oral Exposure.
    Wang J; Susam MM; Gan C; Sparidans RW; Lebre MC; Beijnen JH; Schinkel AH
    Pharmaceuticals (Basel); 2022 Sep; 15(9):. PubMed ID: 36145346
    [TBL] [Abstract][Full Text] [Related]  

  • 54. PI3K-mTOR Pathway Inhibition Exhibits Efficacy Against High-grade Glioma in Clinically Relevant Mouse Models.
    Lin F; de Gooijer MC; Hanekamp D; Chandrasekaran G; Buil LC; Thota N; Sparidans RW; Beijnen JH; Würdinger T; van Tellingen O
    Clin Cancer Res; 2017 Mar; 23(5):1286-1298. PubMed ID: 27553832
    [No Abstract]   [Full Text] [Related]  

  • 55. Interactions between Maraviroc and the ABCB1, ABCG2, and ABCC2 Transporters: An Important Role in Transplacental Pharmacokinetics.
    Tupova L; Ceckova M; Ambrus C; Sorf A; Ptackova Z; Gaborik Z; Staud F
    Drug Metab Dispos; 2019 Sep; 47(9):954-960. PubMed ID: 31266750
    [TBL] [Abstract][Full Text] [Related]  

  • 56. P-Glycoprotein (ABCB1/MDR1) and BCRP (ABCG2) Limit Brain Accumulation and Cytochrome P450-3A (CYP3A) Restricts Oral Exposure of the RET Inhibitor Selpercatinib (RETEVMO).
    Wang Y; Sparidans RW; Potters S; Şentürk R; Lebre MC; Beijnen JH; Schinkel AH
    Pharmaceuticals (Basel); 2021 Oct; 14(11):. PubMed ID: 34832869
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Impact of P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) on the brain distribution of a novel BRAF inhibitor: vemurafenib (PLX4032).
    Mittapalli RK; Vaidhyanathan S; Sane R; Elmquist WF
    J Pharmacol Exp Ther; 2012 Jul; 342(1):33-40. PubMed ID: 22454535
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Influence of breast cancer resistance protein and P-glycoprotein on tissue distribution and excretion of Ko143 assessed with PET imaging in mice.
    Mairinger S; Zoufal V; Wanek T; Traxl A; Filip T; Sauberer M; Stanek J; Kuntner C; Pahnke J; Müller M; Langer O
    Eur J Pharm Sci; 2018 Mar; 115():212-222. PubMed ID: 29360507
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ABCG2 and ABCB1 Limit the Efficacy of Dasatinib in a PDGF-B-Driven Brainstem Glioma Model.
    Mittapalli RK; Chung AH; Parrish KE; Crabtree D; Halvorson KG; Hu G; Elmquist WF; Becher OJ
    Mol Cancer Ther; 2016 May; 15(5):819-29. PubMed ID: 26883271
    [TBL] [Abstract][Full Text] [Related]  

  • 60. P-glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Main Active Heroin Metabolites 6-monoacetylmorphine (6-MAM) and Morphine in Mice.
    F Martins ML; Loos NHC; El Yattouti M; Offeringa L; Heydari P; Hillebrand MJX; Lebre MC; Beijnen JH; Schinkel AH
    Pharm Res; 2023 Aug; 40(8):1885-1899. PubMed ID: 37344602
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.